MANAGEMENT OF STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE : A SYSTEMATIC REVIEW

Chrysman Andreria Hatulely
{"title":"MANAGEMENT OF STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE : A SYSTEMATIC REVIEW","authors":"Chrysman Andreria Hatulely","doi":"10.53555/nnmhs.v9i8.1806","DOIUrl":null,"url":null,"abstract":"Introduction: The goal of drug treatment for chronic obstructive pulmonary disease (COPD) is to relieve symptoms and lower the chance of future problems like flare-ups, disease progression, and death. Because COPD is not all the same, people respond differently to drug treatments. The best way to treat COPD now is with precision medicine, which uses clinical and biomarker data to make treatment decisions that are best for each person. \nThe aim: This article discusses management of stable chronic obstructive pulmonary disease. \nMethods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. \nResult: In the PubMed database, the results of our search brought up 68 articles, whereas the results of our search on SagePub brought up 32 articles. The results of the search conducted for the last year of 2013 yielded a total 31 articles for PubMed and 15 articles for SagePub. In the end, we compiled a total of 14 papers, 10 of which came from PubMed and four of which came from SagePub. We included four research that met the criteria. \nConclusion: COPD treatment has evolved to match clinical characteristics and biomarkers to each patient. Hospitalizations and death have improved in triple combination treatment studies.  However, COPD treatments are lacking, such as emphysema-slowing drugs. Despite progress, much remains.","PeriodicalId":347955,"journal":{"name":"Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53555/nnmhs.v9i8.1806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The goal of drug treatment for chronic obstructive pulmonary disease (COPD) is to relieve symptoms and lower the chance of future problems like flare-ups, disease progression, and death. Because COPD is not all the same, people respond differently to drug treatments. The best way to treat COPD now is with precision medicine, which uses clinical and biomarker data to make treatment decisions that are best for each person. The aim: This article discusses management of stable chronic obstructive pulmonary disease. Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Result: In the PubMed database, the results of our search brought up 68 articles, whereas the results of our search on SagePub brought up 32 articles. The results of the search conducted for the last year of 2013 yielded a total 31 articles for PubMed and 15 articles for SagePub. In the end, we compiled a total of 14 papers, 10 of which came from PubMed and four of which came from SagePub. We included four research that met the criteria. Conclusion: COPD treatment has evolved to match clinical characteristics and biomarkers to each patient. Hospitalizations and death have improved in triple combination treatment studies.  However, COPD treatments are lacking, such as emphysema-slowing drugs. Despite progress, much remains.
稳定期慢性阻塞性肺疾病的治疗:系统综述
慢性阻塞性肺疾病(COPD)药物治疗的目标是缓解症状和降低未来问题的机会,如突然发作、疾病进展和死亡。由于慢性阻塞性肺病并不完全相同,人们对药物治疗的反应也不同。目前治疗慢性阻塞性肺病的最佳方法是使用精准医疗,它利用临床和生物标志物数据来做出最适合每个人的治疗决定。目的:探讨稳定期慢性阻塞性肺疾病的治疗。方法:通过与系统评价和荟萃分析首选报告项目(PRISMA) 2020设定的标准进行比较,本研究能够显示其满足所有要求。因此,专家们能够确保这项研究尽可能是最新的。在这种搜索方法中,研究人员考虑了2013年至2023年之间发表的出版物。几个不同的在线参考资源,如Pubmed和SagePub,被用来做这件事。决定不考虑评论文章、已经发表的作品或只完成一半的作品。结果:在PubMed数据库中,我们搜索的结果是68篇文章,而在SagePub上搜索的结果是32篇文章。2013年最后一年的搜索结果为PubMed提供了31篇文章,SagePub提供了15篇文章。最后,我们一共编辑了14篇论文,其中10篇来自PubMed, 4篇来自SagePub。我们纳入了四项符合标准的研究。结论:COPD治疗已经发展到与每位患者的临床特征和生物标志物相匹配。在三联治疗研究中,住院率和死亡率有所改善。然而,慢性阻塞性肺病治疗缺乏,如肺气肿减缓药物。尽管取得了进展,但仍有许多问题有待解决。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信